NovoCure(NVCR)
$11.83+0.11 (+0.94%)
NVCR
NovoCure stock drug pipeline
$11.83
At close:+0.11 (+0.94%)
Want to see NVCR full AI Analyst Report?
NovoCure (NVCR) Drug Pipeline
1,591 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pembrolizumab, Temozolomide, Optune® Device | Glioblastoma | Phase III | Recruiting | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Aug 13, 2024 | ― |
| Pembrolizumab, Novottf-200T | Non-Small Cell Lung Cancer (Nsclc) | Phase II | Recruiting | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) | Jul 31, 2024 | ― |
| Gemcitabine, Nab-paclitaxel, Atezolizumab, Tumor Treating Fields | Metastatic Pancreatic Ductal Adenocarcinoma | Phase II | Active Not Recruiting | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | Feb 29, 2024 | ― |
| Pembrolizumab, Novottf-200T, Platinum Based Chemotherapy | Metastatic Non-Small Cell Lung Cancer | Phase III | Recruiting | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Dec 29, 2023 | ― |
| Novottf-200T, Pembrolizumab (Mk-3475) 200 Mg | Non-small Cell Lung Cancer | Phase II | Terminated | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer | May 13, 2021 | ― |
| Sorafenib, Novottf-100L(P) Device | Hepatocellular Carcinoma | Phase II | Completed | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | Jul 23, 2018 | ― |
| Gemcitabine, Nab Paclitaxel, Novottf-200T | Pancreas Adenocarcinoma | Phase III | Completed | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | Dec 06, 2017 | ― |
| Best Standard Of Care, Novottf-200M Device | Brain Metastases From Non-Small Cell Lung Cancer (Nsclc) | Phase III | Completed | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). | Jul 08, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pembrolizumab, Temozolomide, Optune® Device | Phase III | Glioblastoma | Recruiting | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Aug 13, 2024 | ― |
| Pembrolizumab, Novottf-200T | Phase II | Non-Small Cell Lung Cancer (Nsclc) | Recruiting | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) | Jul 31, 2024 | ― |
| Gemcitabine, Nab-paclitaxel, Atezolizumab, Tumor Treating Fields | Phase II | Metastatic Pancreatic Ductal Adenocarcinoma | Active Not Recruiting | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | Feb 29, 2024 | ― |
| Pembrolizumab, Novottf-200T, Platinum Based Chemotherapy | Phase III | Metastatic Non-Small Cell Lung Cancer | Recruiting | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Dec 29, 2023 | ― |
| Novottf-200T, Pembrolizumab (Mk-3475) 200 Mg | Phase II | Non-small Cell Lung Cancer | Terminated | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer | May 13, 2021 | ― |
| Sorafenib, Novottf-100L(P) Device | Phase II | Hepatocellular Carcinoma | Completed | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | Jul 23, 2018 | ― |
| Gemcitabine, Nab Paclitaxel, Novottf-200T | Phase III | Pancreas Adenocarcinoma | Completed | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | Dec 06, 2017 | ― |
| Best Standard Of Care, Novottf-200M Device | Phase III | Brain Metastases From Non-Small Cell Lung Cancer (Nsclc) | Completed | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). | Jul 08, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does NovoCure Ltd. (NVCR) have in its pipeline
NovoCure NVCR is currently developing the following drugs: Pembrolizumab, Temozolomide, Optune® Device, Pembrolizumab, Novottf-200T, Gemcitabine, Nab-paclitaxel, Atezolizumab, Tumor Treating Fields, Pembrolizumab, Novottf-200T, Platinum Based Chemotherapy, Novottf-200T, Pembrolizumab (Mk-3475) 200 Mg, Sorafenib, Novottf-100L(P) Device, Gemcitabine, Nab Paclitaxel, Novottf-200T, Best Standard Of Care, Novottf-200M Device. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
